This implies that to achieve the most effective immunotherapy in PD-L2 expressing cancers like HNSCC, RCC, and LUSC, it’s essential to consider blocking the PD-1/PD-L2 interaction (141). The gene discussed is PDCD1LG2; the disease is head and neck squamous cell carcinoma.